Stock ALTME TME PHARMA N.V.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : TME Pharma N.V.

TME Pharma N.V. Stock price

Equities

ALTME

NL0015000YE1

Biotechnology & Medical Research

Market Closed - Euronext Paris
Other stock markets
 11:20:05 2023-12-05 EST 		Intraday chart for TME Pharma N.V. 5-day change 1st Jan Change
0.25 EUR -3.85% 0.00% -79.44%
11-28 TME PHARMA : Invest Securities updates its target CF
11-27 TME Pharma: shares fall after capital increase CF

Financials

Sales 2023 * 40K 43.17K 58.6K Sales 2024 * 5.04M 5.44M 7.38M Capitalization 1.33M 1.43M 1.94M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 *
18,9x
Net cash position 2023 * 570K 615K 835K Net cash position 2024 * 1.57M 1.69M 2.3M EV / Sales 2024 *
-0,05x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 13
Yield 2023 *
-
Yield 2024 *
-
Free-Float 32.38%
More Fundamentals * Assessed data

Chart TME Pharma N.V.

Dynamic Chart

Latest news about TME Pharma N.V.

TME PHARMA : Invest Securities updates its target CF
TME Pharma: shares fall after capital increase CF
TME Pharma N.V. announced that it expects to receive ?2.7 million in funding CI
TME Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
TME Pharma N.V. Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer CI
TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting CI
Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer CI
TME Pharma N.V. Provides Positive Data Update on Best Response to Therapy with First Complete Response in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near- Complete Response CI
TME Pharma N.V. Announces Positive 15-Month Survival Data from Gloria Expansion Arm Evaluating NOX-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma CI
Appetite for Risk Surges
TME Pharma N.V. Receives Investigational New Drug Approval for NOX-A12 From the US FDA CI
TME Pharma N.V. Provides Positive Clinical Update and 14-Month Survival Data from Gloria Expansion Arm Evaluating Nox-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma CI
TME Pharma N.V. Auditor Raises 'Going Concern' Doubt CI
TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TME Pharma N.V. Announces a Clinical Update on Survival of Newly Diagnosed Glioblastoma Patients in the GLORIA Expansion Arm Evaluating NOX-A12, TME Pharma’s CXCL12 Inhibitor CI
More news

Analyst Recommendations on TME Pharma N.V.

TME PHARMA : Invest Securities updates its target CF
More recommendations

Press releases TME Pharma N.V.

TME PHARMA ANNOUNCES THE INITIATION OF THE LISTING OF PREFERENTIAL SUBSCRIPTION RIGHTS FOR FULLY GUARANTEED EUR2.7 MILLION CAPITAL INCREASE AQ
TME PHARMA LAUNCHES FULLY GUARANTEED EUR2.7 MILLION PREFERENTIAL RIGHTS ISSUE WITH WARRANTS ATTACHED COMBINED WITH BUYBACK OF CONVERTIBLE DEBT AQ
TME Pharma N : Inside Information / Operations of the issuer (acquisitions, sales...) PU
TME PHARMA ANNOUNCES ADDITIONAL DATA FROM NOX-A12 COMBINATION REGIMEN IN BRAIN CANCER PRESENTED AT SNO 2023 ANNUAL MEETING AQ
TME PHARMA REPORTS H1 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE AQ
More press releases

News in other languages on TME Pharma N.V.

TME PHARMA : Invest Securities met sa cible à jour
TME Pharma : le titre chute après une augmentation de capital
Comme un petit vent de prises de bénéfices
Les valeurs à suivre aujourd'hui à la Bourse de Paris - Lundi 27 novembre 2023
En Direct des Marchés : L'Oréal, Veolia, Casino, Valneva, Novo Nordisk, Julius Bär...
More news

Quotes and Performance

1 day-3.85%
Current month-7.41%
1 month-38.57%
3 months-85.62%
6 months-81.99%
Current year-79.44%
More quotes

Highs and lows

1 week
0.24
Extreme 0.242
0.29
1 month
0.24
Extreme 0.24
0.47
Current year
0.24
Extreme 0.24
2.20
1 year
0.24
Extreme 0.24
2.20
3 years
0.24
Extreme 0.24
71.00
5 years
0.24
Extreme 0.24
206.00
10 years
0.24
Extreme 0.24
2 200.00
More quotes

Managers and Directors - TME Pharma N.V.

Managers TitleAgeSince
Aram Andrew Mangasarian CEO
 Chief Executive Officer 54 2010
Heike Balzer DFI
 Director of Finance/CFO - 1999
Ewelina Staniuk IRC
 Investor Relations Contact - 2017
Members of the board TitleAgeSince
Cornelis Alexander Izeboud BRD
 Director/Board Member 52 2020
Maurizio PetitBon CHM
 Chairman 75 2016
Susan Coles BRD
 Director/Board Member 57 2021
More insiders

Quotes

Date Price Change Volume
23-12-05 0.25 -3.85% 65,434
23-12-04 0.26 +4.42% 48,355
23-12-01 0.249 -7.78% 384,489
23-11-30 0.27 +4.25% 121,956
23-11-29 0.259 +3.60% 477,613

Real-time Euronext Paris, December 05, 2023 at 11:20 am

More quotes

Company Profile

TME Pharma N.V. is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. The company specializes in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Its unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma N.V.'s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Its clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
Sector
Biotechnology & Medical Research
Calendar
2024-04-23 - Q4 2023 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.25EUR
Average target price
3.52EUR
Spread / Average Target
+1,308.00%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TME PHARMA N.V. Stock TME Pharma N.V.
-79.44% 1 M $
SEAGEN INC. Stock Seagen Inc.
+67.95% 40 719 M $
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+4.60% 39 112 M $
MODERNA, INC. Stock Moderna, Inc.
-56.42% 29 847 M $
LONZA GROUP AG Stock Lonza Group AG
-26.33% 28 329 M $
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+38.74% 22 187 M $
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-28.31% 21 380 M $
CELLTRION, INC. Stock Celltrion, Inc.
+1.31% 17 155 M $
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
-13.59% 11 293 M $
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-22.32% 10 182 M $
Other Biotechnology & Medical Research
  1. Stock
  2. Equities
  3. Stock TME Pharma N.V. - Euronext Paris
The best tools reserved for subscribers to boost the performance of your investments!
Optimize my profits
fermer
Etats-Unis

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition